Author

Ronald Jara

Austral University of ChileORCID 0009-0005-2861-3911Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Microbiology· 1 Molecular Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Assay:proteomics· 2 Research Focus:host-pathogen & immune response· 1 Research Focus:protein folding & dynamics· 1

Frequent Co-Authors

Alejandro Rojas‐FernándeziD· 3 shared Constanza Salinas-RebolledoiD· 3 shared Guillermo ValenzuelaiD· 3 shared Alexander A. KhromykhiD· 2 shared Camila Deride· 2 shared Daniel WattersoniD· 2 shared David SchwefeliD· 2 shared Javier BlesaiD· 2 shared

Activity by Year

2021-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersBiochemistry

Alejandro Rojas‐FernándezORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

BiochemistryeLifePeer-reviewedNov 25, 2025

Specific proteolysis mediated by a p97-directed proteolysis-targeting chimera (PROTAC)

Constanza Salinas-Rebolledo, Javier Blesa, Guillermo Valenzuela…·Alejandro Rojas‐Fernández

This paper describes the engineering of a PROTAC that uses p97-directed proteolysis to achieve specific substrate degradation without relying on E3 ubiquitin ligases.

3 citations

proteomicsexperimental assay

𝕏 PostBluesky

MicrobiologybioRxivPreprintMar 11, 2025

A protective bispecific antibody targets both Nipah virus surface glycoproteins and limits viral escape

Ariel Isaacs, Guillermo Valenzuela, Xinghai Zhang…·Daniel Watterson

This paper develops a bispecific antibody that targets both Nipah virus surface glycoproteins, reducing viral escape and enhancing protection against NiV disease.

3 citations

experimental assayhost-pathogen & immune response

𝕏 PostBluesky

Molecular BiologyScientific ReportsPeer-reviewedFeb 8, 2021

Potent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity Nanobody.

Guillermo Valenzuela, Ronald Jara, Daniel Watterson…·Alejandro Rojas‐Fernández

The paper describes the development of a high-affinity Nanobody against SARS-CoV-2 RBD that neutralizes wild-type and D614G variants with nanomolar potency.

57 citations

proteomicsexperimental assay

𝕏 PostBluesky